Supplemental Material: Cost of Home vs Clinic Administration of Paclitaxel in Metastatic Breast Cancer

December 24, 2020
Dolly Sharma, PhD

,
Jeffrey Wojtynek, PharmD

,
Kathleen M. Fox, PhD

,
Chelsea Cooper, PharmD

,
Igoni Dokubo, MD

Evidence-Based Oncology, February 2021, Volume 27, Issue 2

Home administration of oral paclitaxel and encequidar is associated with potential cost savings for payers compared with clinic administration of intravenous chemotherapy in metastatic breast cancer patients.